Exploring the Critical Elements of Hyperkalemia: A Hospital Pharmacist's Perspective
This Continuing Education activity is supported by an educational grant from Relypsa, Inc.
This activity is supported by an educational grant from Relypsa, Inc.
Kelly Harbourt, PharmD, BCPS
Department of Clinical and Administrative Sciences
Notre Dame of Maryland University, School of Pharmacy
Clinical Pharmacy Specialist
R. Adams Cowley Shock Trauma Center
University of Maryland Medical Center
After completing this continuing education program, the participant will be able to:
- Examine the epidemiology of hyperkalemia and its impact as a major barrier in the optimal use of essential therapy in patients with cardiovascular and renal disease.
- Explore the pathophysiology of hyperkalemia, particularly in association with inhibition of the renin—aldosterone– angiotensin system.
- Identify opportunities for the hospital pharmacist to intervene to minimize the risk for hyperkalemia.
- Demonstrate corrective measures for hyperkalemia, and address the role of newer potassium-binding resins.
Target audience: Health-system p
Type of activity: Application
Release date: May 15, 2016
Expiration date: May 15, 2017
Estimated time to complete activity: 2.0 hours
Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-16-059-H01-P. The activity is available for CE credit through May 15, 2017.